ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,948Medicare Part D Prescriptions Filled, Including Refills

Rank: 110 out of 617

$382K Total Retail Price of All Prescriptions

Rank: 164 out of 617

399 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
28% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 399 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

17% of this provider’s 399 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 8,580 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$38 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
SIMVASTATIN 418 390 1 2
LISINOPRIL 340 303 2 5
LEVOTHYROXINE SODIUM 339 319 3 1
OMEPRAZOLE 337 309 4 3
WARFARIN SODIUM 317 317 5 7
HYDROCODONE-ACETAMINOPHEN 285 251 S3 6 8
METFORMIN HCL 270 252 7 9
FUROSEMIDE 250 193 8 4
ALLOPURINOL 223 223 9 27
POTASSIUM CHLORIDE 211 164 10 10
LOVASTATIN 198 198 11 57
METOPROLOL TARTRATE 195 186 12 11
PREDNISONE 187 169 13 31
AMLODIPINE BESYLATE 178 167 14 6
SYNTHROID 174 122 15 59
LISINOPRIL-HYDROCHLOROTHIAZIDE 164 158 16 29
METOPROLOL SUCCINATE 162 145 17 12
TRAMADOL HCL 158 121 18 15
GABAPENTIN 154 133 19 16
ZOLPIDEM TARTRATE 137 102 20 23
TRIAMTERENE-HCTZ 121 117 21 47
ATORVASTATIN CALCIUM 121 106 21 14
ATENOLOL 114 107 23 17
AMLODIPINE BESYLATE-BENAZEPRIL 107 107 24 80
SERTRALINE HCL 106 86 25 20
POLYETHYLENE GLYCOL 3350 98 91 26 32
CARVEDILOL 82 72 27 19
TIZANIDINE HCL 76 32 28 180
FAMOTIDINE 72 54 29 54
CLONIDINE HCL 72 59 29 55
MELOXICAM 70 65 31 24
OXYBUTYNIN CHLORIDE 70 49 31 88
TRAZODONE HCL 69 65 33 51
FLUTICASONE PROPIONATE 66 54 34 36
SPIRONOLACTONE 63 57 35 42
HYDROCHLOROTHIAZIDE 63 63 35 13
HUMULIN N 61 53 37 284
CRESTOR 59 47 38 28
DONEPEZIL HCL 53 53 39 30
NOVOLIN N 53 33 39 310
CITALOPRAM HBR 52 52 41 18
SULFAMETHOXAZOLE-TRIMETHOPRIM 51 47 42 91
LOSARTAN POTASSIUM 51 39 42 22
LOSARTAN-HYDROCHLOROTHIAZIDE 50 47 44 46
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 28, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.